pyrazinamide has been researched along with leucine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Berkers, CR; Groll, M; Ovaa, H; Ploegh, HL | 1 |
| Fattal, E; Ghermani, N; Guiblin, N; Pham, DD; Tsapis, N | 1 |
| Kaewjan, K; Srichana, T | 1 |
| Das, SC; Eedara, BB; Tucker, IG | 1 |
| Cavallaro, A; Das, SC; Doyle, C; Eedara, BB; Rangnekar, B | 1 |
| Abbas, SN; Bhatti, S; Mahmood, N; Nasir, SB; Shahid, S | 1 |
7 other study(ies) available for pyrazinamide and leucine
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Catalytic Domain; Crystallization; Leucine; Mammals; Models, Molecular; Peptides; Phenylalanine; Proteasome Endopeptidase Complex; Protein Structure, Quaternary; Pyrazinamide; Pyrazines; Structure-Activity Relationship; Substrate Specificity; Yeasts | 2006 |
Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: avoiding crystal growth using excipients.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Administration, Inhalation; Antitubercular Agents; Bicarbonates; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Crystallization; Excipients; Hyaluronic Acid; Leucine; Particle Size; Porosity; Powder Diffraction; Pyrazinamide; X-Ray Diffraction | 2013 |
Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.
Topics: Aerosols; Chemistry, Pharmaceutical; Dry Powder Inhalers; Feasibility Studies; Leucine; Nanoparticles; Particle Size; Powders; Pyrazinamide; X-Ray Diffraction | 2016 |
Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Administration, Inhalation; Aerosols; Antitubercular Agents; Chemistry, Pharmaceutical; Desiccation; Drug Delivery Systems; Dry Powder Inhalers; Excipients; Leucine; Lung; Nanoparticles; Particle Size; Phosphatidylethanolamines; Phospholipids; Polyethylene Glycols; Powders; Pyrazinamide; Tuberculosis | 2016 |
The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Aerosols; Antitubercular Agents; Chemistry, Pharmaceutical; Desiccation; Excipients; Fluoroquinolones; Leucine; Moxifloxacin; Particle Size; Powders; Pyrazinamide | 2018 |
The pncA gene mutations of Mycobacterium tuberculosis in multidrug-resistant tuberculosis.
Topics: Adult; Alanine; Amidohydrolases; Antitubercular Agents; Aspartic Acid; Bacterial Proteins; Codon; Cross-Sectional Studies; Humans; Leucine; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Proline; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Young Adult | 2022 |